Skip to main content
OpenTrials
Completed

NCT Number: NCT01043198

Microarray Analysis in Syndromic Obesity

Comparative genomic hybridization (CGH) array technology has been used in numerous studies on mental retardation, and few chromosomal abnormalities have been identified in patients. Because chromosomal abnormalities have still been associated with obesity, we can expect that syndromic obesity is also associated with small deletions/duplications. Characterization of deleted or duplicated loci in these obese patients would mean that these loci include genes implicated in obesity. This will permit to propose new gene(s) involved in obesity. (In french: Caractérisation phénotypique et recherche de REManiements chromosomiques chez des patients présentant une OBésité syndromique de cause non identifiée : REMOB)

Completed

Looking for future studies?

Notify Me

Key information

Age range

Up to 18 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Service de Génétique de médicale - Hopital des enfants - Pellegrin, Bordeaux, France

Loading trial locations.

About this study

With the introduction of array comparative genomic hybridization (CGH), genome-wide high resolution analysis for DNA copy number alterations became feasible. This technology has been principally used in patients with mental retardation. Depending on the eligibility criteria and resolution of the array, around 10 % of patients with mental retardation are found with cryptic chromosomal imbalance. This figure arises 20 % for patients with mental retardation and multiple congenital anomalies. Alteration of the lipid metabolism and/or regulation of satiety, obesity (except in presence of other "exogen" factors) can be considered as a developmental disorder. Also, different syndromes with obesity have been associated with chromosomal abnormalities, such as 1p36 deletion syndrome, 2q37 deletion syndrome, chromosome 14 maternal disomy … So we can expect that syndromic obesity is similarly associated with sub cryptic chromosomal abnormalities. Some "isolated" patients with obesity have been described with cryptic chromosomal imbalance found by array CGH, but no study has been realized in cohorts of patients selected for syndromic obesity.

Characterization of cryptic chromosomal anomaly(ies) in a patient will also be useful to precise the management and follow-up of the patient and to give the family an adapted genetic counselling.

We will define a cohort of patients with syndromic obesity and propose them to realize a first screening looking for the "common" aetiologies of syndromic obesity. If this screening is normal, array CGH will be realized. This analysis implies a blood sampling of 5 ml in patient and his parents.

Genes present at the deleted or duplicated loci characterized in the patients will be study to determine if some could be specifically implicated in the development of obesity. These same genes could be implicated in isolated obesity. Our study will be also useful to precise the aetiological screening of syndromic obesity, and determine the place of array-CGH.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • children (under 18 year-old)
  • obesity (following IOTF definition)
  • at least one criteria among :
  • mental retardation
  • facial dysmorphism
  • at least one major malformation (uro-genital, cardiac, skeletal, cerebral, ophthalmologic…)

Exclusion criteria

  • common obesity
  • obesity with an identified aetiology

Treatment and study plan

Clinical examination and blood sampling for biological and genetic analysis

Genetic

Clinical examination and precise description of the phenotype (questionnaire)

  • Standardized screening with :
  • radiological (hands, feet, spine ; and renal ultrasonography)
  • biological (hormonal, metabolic, and "basic" genetic investigations (karyotype, FISH 22q11.2, Fragile X, and other depending on the clinical data))

Primary outcomes

  1. Evaluation of the prevalence of cryptic chromosomal imbalance in patients with syndromic obesity of unknown etiology.

    Time frame: 3 - 6 months

Secondary outcomes

  1. prevalence of the main genetic aetiologies of syndromic obesity

    Time frame: 3 - 6 months

  2. Characterization of the main features evocative of subcryptic chromosomal anomalies in this population

    Time frame: 3 - 6 months

  3. Phenotypic description of some "new" syndromes with obesity

    Time frame: 3 - 6 months

  4. candidate genes implicated in the development of obesity.

    Time frame: 3 - 6 months

  5. Delineation of an aetiological screening protocol in patients with syndromic obesity

    Time frame: 3 - 6 months

Sponsors and collaborators

Lead sponsor

University Hospital, Bordeaux

Other

Registry information

Official study title

Phenotypic Characterization and Array CGH Analysis in Patients With Syndromic Obesity of Unknown Etiology

Acronym: REMOB

Important dates

Study start
2010
Primary completion
2011
Study completion
2011
First posted
Jan 6, 2010
Registry last updated
May 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.